28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

PHASE1UnknownINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

February 5, 2019

Study Completion Date

February 5, 2020

Conditions
Healthy MenMale Contraception
Interventions
DRUG

Placebo

Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.

DRUG

11β-methyl-nortestosterone-dodecylcarbonate

11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.

Trial Locations (2)

90509

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

98195

University of Washington Medical Center & Health Sciences, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

collaborator

University of Washington

OTHER

lead

Premier Research

OTHER

NCT03298373 - 28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men | Biotech Hunter | Biotech Hunter